Vaxcyte Management

Management criteria checks 3/4

Vaxcyte's CEO is Grant Pickering, appointed in Nov 2013, has a tenure of 10.92 years. total yearly compensation is $12.14M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 0.54% of the company’s shares, worth €68.02M. The average tenure of the management team and the board of directors is 4.4 years and 5.5 years respectively.

Key information

Grant Pickering

Chief executive officer

US$12.1m

Total compensation

CEO salary percentage	5.3%
CEO tenure	10.9yrs
CEO ownership	0.5%
Management average tenure	4.4yrs
Board average tenure	5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Grant Pickering's remuneration changed compared to Vaxcyte's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$497m
Mar 31 2024	n/a	n/a	-US$437m
Dec 31 2023	US$12m	US$640k	-US$402m
Sep 30 2023	n/a	n/a	-US$300m
Jun 30 2023	n/a	n/a	-US$265m
Mar 31 2023	n/a	n/a	-US$245m
Dec 31 2022	US$14m	US$601k	-US$223m
Sep 30 2022	n/a	n/a	-US$174m
Jun 30 2022	n/a	n/a	-US$143m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$5m	US$575k	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$87m
Mar 31 2021	n/a	n/a	-US$83m
Dec 31 2020	US$3m	US$481k	-US$89m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	n/a	n/a	-US$64m
Dec 31 2019	US$596k	US$426k	-US$50m

Compensation vs Market: Grant's total compensation ($USD12.14M) is above average for companies of similar size in the German market ($USD5.11M).

Compensation vs Earnings: Grant's compensation has been consistent with company performance over the past year.

CEO

Grant Pickering (56 yo)

10.9yrs

Tenure

US$12,135,683

Compensation

Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Grant Pickering	Co-Founder	10.9yrs	US$12.14m	0.54% $ 68.0m
Andrew Guggenhime	President & CFO	4.4yrs	US$5.42m	0.044% $ 5.6m
James Wassil	Executive VP & COO	4.8yrs	US$5.40m	0.14% $ 17.0m
Mikhail Eydelman	Senior VP	2.5yrs	US$3.49m	0.0082% $ 1.0m
Ashish Khanna	Co-Founder	11.8yrs	no data	no data
Jeff Fairman	Co-Founder & VP of Research	no data	no data	no data
Elvia Cowan	Senior VP of Finance & Principal Accounting Officer	1.8yrs	no data	0.0032% $ 396.3k
Janet Graesser	Senior Vice President of Corporate Communications & Investor Relations	no data	no data	no data
Whitney Jones	Chief People Officer	less than a year	no data	no data
Paul Sauer	Senior Vice President of Process Development & Manufacturing	8.5yrs	US$2.35m	no data
Harp Dhaliwal	Senior Vice President of Commercial Manufacturing & Supply Chain	2.9yrs	US$1.84m	no data
Sam Iki	Senior Vice President of Project Management	no data	no data	no data

4.4yrs

Average Tenure

55yo

Average Age

Experienced Management: 5VA's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Grant Pickering	Co-Founder	10.9yrs	US$12.14m	0.54% $ 68.0m
Thomas Monath	Member of Scientific Advisory Board	no data	no data	no data
Annie Drapeau	Independent Director	3.1yrs	US$704.22k	0.0046% $ 570.7k
K. Hirth	Independent Director	8.1yrs	US$696.72k	0.010% $ 1.3m
Heath Lukatch	Independent Director	6.4yrs	US$691.72k	0.0046% $ 570.7k
Halley Gilbert	Independent Director	4.5yrs	US$704.22k	0.0046% $ 570.7k
Emmanuel Walter	Member of Scientific Advisory Board	no data	no data	no data
Carlos Paya	Independent Chairman of the Board	3yrs	US$724.22k	0.0046% $ 570.7k
Anthony Ford-Hutchinson	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Almond	Member of Scientific Advisory Board	7.8yrs	no data	no data
Teri Loxam	Independent Director	3.1yrs	US$704.22k	0.0046% $ 570.7k
William Hausdorff	Member of Scientific Advisory Board	no data	no data	no data

5.5yrs

Average Tenure

57yo

Average Age

Experienced Board: 5VA's board of directors are considered experienced (5.5 years average tenure).

Vaxcyte Management

Management criteria checks 3/4

Key information

Recent management updates

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

Recent updates

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

New major risk - Shareholder dilution

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

High number of new directors

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

High number of new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age